Showing results (61-70 of 154) with videos related to
Sort By:
Pageof 16
JID Innovations : Skin Science From Molecules to Population Health|September 5, 2022
Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic DermatitisLisa A Beck, Michael J Cork, Masayuki Amagai, et al.International Journal of Radiation Oncology, Biology, Physics|April 15, 2011
Fibroblast growth factor-peptide improves barrier function and proliferation in human keratinocytes after radiationKunzhong Zhang, Yeping Tian, Liangjie Yin, et al.Allergy|July 31, 2026
Serum-Proteomic Profiling Reveals Distinct Atopic Dermatitis Severity-Linked SignaturesJag S Lally, Takeshi Yoshida, Shan Gao, et al.Journal of Virology|August 9, 2013
Sustained protein kinase D activation mediates respiratory syncytial virus-induced airway barrier disruptionFariba Rezaee, Samantha A DeSando, Andrei I Ivanov, et al.Dermatology and Therapy|September 12, 2025
Real-World Onset of Atopic Comorbidities Relative to Atopic Dermatitis in Pediatric PatientsYael A Leshem, Clara Weil, William W Busse, et al.Msphere|December 13, 2019
Staphylococcal Virulence Factors on the Skin of Atopic Dermatitis PatientsMary C Moran, Michael P Cahill, Matthew G Brewer, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|February 15, 2024
Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitisJulie Ryan Wolf, Anita Chen, Jill Wieser, et al.Pediatrics|March 4, 2003
Atopic dermatitis and asthma: parallels in the evolution of treatmentLawrence F Eichenfield, Jon M Hanifin, Lisa A Beck, et al.The British Journal of Dermatology|July 22, 2026
Delgocitinib cream formulation demonstrates a dose-dependent response in adults with mild to severe atopic dermatitis: results from an 8-week randomised Phase IIb trialJonathan I Silverberg, Lisa A Beck, Melinda Gooderham, et al.The Journal of Dermatological Treatment|February 9, 2021
Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension studyLisa A Beck, Diamant Thaçi, Mette Deleuran, et al.Pageof 16